In this paper, we propose an impulsive mathematical model of bone formation and resorption accounting for the number of active osteoclastic cells, bone resorbing cells, and the number of active osteoblastic cells, bone forming cells, based on the effects of parathyroid hormone and calcitonin with impulsive estrogen supplement. The model is then analyzed theoretically in terms of its stability, permanence and oscillatory behavior. The conditions on the model parameters, for which the desirable behaviors of the solution of the system can be expected, are derived. Numerical simulations are also carried out in order to support our theoretical predictions. The results indicate that the frequency and dosage of the estrogen supplements are important since the behavior of the solution of the system depends on the frequency and dosage of the estrogen supplements.
Introduction
Bone is a highly organized tissue. Apart from attending to its own structural integrity, the skeleton must also respond to systemic needs for adequate amounts of calcium in the extracellular fluid. In order to maintain normal functions of bone and calcium homeostasis, bone remodeling process is needed to be taken into account. In bone remodeling process, osteoclasts act as bone resorbing cells, while osteoblasts act as bone forming cells. The process begins with the appearance of active osteoclasts on a previously inactive surface of bone, after which a lacuna will be excavated. Subsequently, osteoblasts then refill the resorption cavity and become inactive osteoblasts [-] . Serious health conditions such as osteoporosis may occur when the bone remodeling process is imbalanced (e.g. there is excessively deep resorption space produced by osteoclasts, or the replenishment of the resorption space by the activation of osteoblasts is incomplete). For a better understanding of bone remodeling process, the basic knowledge about osteoblasts, osteoclasts and the involving hormones such as parathyroid hormone (PTH) and calcitonin (CT) is necessary.
Osteoblasts derived from mesenchymal cells are responsible for bone formation. The stromal stem cells proliferate preosteoblast precursors, and then preosteoblasts precur-sors proliferate preosteoblasts. After that, preosteoblasts differentiate into osteoblasts, and then osteoblasts become osteocytes or resting osteoblasts [] . Note that the differentiation and activation of osteoclasts require direct physical contact with osteoblasts that produce at least two indispensable cytokines [] . On the other hand, osteoclasts derived from the hemopoietic cells are responsible for bone resorption. The hemopoietic stem cells proliferate preosteoclast precursor cells, and then preosteoclasts precursors differentiate into preosteoclasts. After that, preosteoclasts differentiate into osteoclasts [] .
PTH and CT are principal hormones involved in bone formation and resorption. PTH is secreted from the parathyroid glands in response to the low calcium level in blood. It increases calcium concentration in blood by various direct and indirect actions on bone, kidney and intestine [] . On bone, PTH enhances bone resorption by stimulating the activation of osteoclasts indirectly through osteoblasts since osteoclasts do not possess PTH receptors while osteoblast precursors possess them. Moreover, PTH has both stimulating and inhibiting effects on the differentiation and activation of osteoblasts [] . PTH stimulates the differentiation of mesenchymal stem cells to preosteoblasts, but it inhibits the differentiation of osteoblasts in mature cells through the process of down-regulation of PTH receptors on osteoblasts [-]. In contrast to PTH, CT produced by the parafollicular cells of the thyroid gland inhibits bone resorption by acting on osteoclasts resulting in the decrease of calcium level in blood [, ].
As discussed above, an excessively deep resorption space produced by osteoclasts or an incomplete replenishment of the resorption space by the activation of osteoblasts can result in bone remodeling imbalance. If remodeling imbalance exists after the completion of a remodeling cycle, the degree of bone loss will be exacerbated and that leads to osteoporosis [] . Osteoporosis is a bone metabolic disease which is characterized by low bone mass, the structural deterioration of bone and an increased risk of fracture. It occurs most frequently in postmenopausal women [] . An increase in the activation frequency of new bone remodeling units and an increase in remodeling imbalance, especially resulting from the increase of osteoclastic formation, are observed when estrogen is deficient [-]. In osteoporosis patients, estrogen replacement therapy has been widely used to prevent menopausal bone loss and reduce the risk of fracture [-]. Kanatani et al. [] and Riggs et al. [] reported that the presence of estrogen results in the decrease of bone resorption by inhibiting the activity of osteoclasts. The works of Prestwood et al. [] and Albright et al. [] indicated the decrease in the values of biochemical markers of bone turnover due to the short-term estrogen treatment. However, there are some serious risks and side effects from the estrogen replacement therapy such as breast cancer and heart disease [, ]. High doses of estrogen results in weight loss in rats, and an increase in tumor formation was observed in aging rats with long-term treatment of estrogen [] . Hence, the appropriate dose and duration of estrogen treatment are necessary and need to be investigated in details.
Mathematical models of bone remodeling process were proposed and analyzed theoretically and numerically [-] . However, the model that incorporates the effects of PTH, CT and the impulsive treatments of estrogen has not been proposed and analyzed yet. In the next section, we will develop a system of impulsive differential equations to study the effects of PTH, CT and the impulsive estrogen replacement therapy on bone remodeling process.
Model development
In bone remodeling process, estrogen is responsible for many osteoclast suppressing activities both directly and indirectly. Estrogen limits the size of preosteoclast and osteoclast populations, and it also limits the production of osteoclasts by restraining the production and secretion of cytokine that stimulate a stimulator of osteoclast development [-]. Moreover, in the presence of estrogen, osteoblastic stromal cells synthesize more antiosteoclast OPG than osteoclast-stimulating receptor activator RANKL. Since OPG is a soluble decoy RANK-like receptor that binds to and covers up RANKL molecules sticking out of the surfaces of osteoblastic stromal cells, then the more OPG means the less RANKL available on the osteoblastic stromal cells' surfaces for binding to their real RANK receptors, and that reduces the RANK signals needed to drive differentiation of the osteoclast progenitors into mature osteoclasts. Hence, the increase in the level of estrogen results in the decrease in the number of osteoclasts [-]. On the other hand, it has been reported that estrogen also has stimulating effects on osteoblasts as well by attenuating PTH-induced inhibition of osteoblast proliferation [, ] . Estrogen also directly modulates differentiation of bipotential stromal cells into the osteoblast and adipocyte lineages, causing a lineage shift toward the osteoblast, which leads to direct stimulation of bone formation [] . We then propose an impulsive model to investigate the effects of PTH, CT and impulsive estrogen treatments on bone remodeling process as follows:
where x(t) denotes the concentration of PTH above the basal level in blood at time t, y(t) denotes the concentration of CT above the basal level in blood at time t, z(t) denotes the number of active osteoclasts at time t, w(t) denotes the number of active osteoblasts at time t and all parameters in the model are positive constant.
, T represents the period of impulsive treatment of estrogen, n ∈ Z + , Z + = {, , , . . .}, ρ represents the inhibiting effect of estrogen supplement on osteoclasts,  < ρ < , and μ represents the stimulating effect of estrogen supplement on osteoblasts, μ > . Here, the rate of change of PTH concentration in blood is represented by (a). The first term on the right-hand side accounts for the secretion rate of PTH from the parathyroid glands which is inhibited by the increase in the calcium levels indicated by the increase in the number of active osteoclasts [] .
The rate of change of CT concentration in blood is represented by (b). The elevation of calcium levels indicated by the increase in the number of active osteoclasts stimulates the secretion of CT from the thyroid gland, whereas the increase in the level of PTH suppresses the secretion of CT as reported in [] . Hence, the secretion rate of CT is then assumed to be represented by the first term on the right-hand side of (b).
The rate of change of the number of active osteoclasts is represented by (c). The first term on the right-hand side accounts for the stimulating effect of PTH and the inhibiting effect of CT on the reproduction of active osteoclasts which requires the cell to cell interaction of osteoclasts and osteoblasts as indicated in [] .
The rate of change of the number of active osteoblasts is represented by (d). The first and the second terms on the right-hand side account for the stimulating effect and the inhibiting effect of PTH on the reproduction and differentiation of active osteoblasts as mentioned in [], respectively.
The last terms of (a)-(d) account for the removal rates of PTH, CT, active osteoclasts and active osteoblasts, respectively.
The inhibition effect of estrogen treatment on the number of active osteoclasts is represented by (e), while the stimulating effect of estrogen treatment on the number of active osteoblasts is represented by (f).
As it has been observed clinically in [, , ], the dynamics of PTH and CT are very fast compared to the changes in the number of active osteoclasts and active osteoblasts. We then assume in what follows that PTH and CT equilibrate quickly to the level at which dx dt =  and dy dt = , respectively. That is,
and
Hence, system (a)-(f) can be reduced to the system of (a)-(d) as follows:
Preliminaries
Let
where
The map defined by the right-
, the upper right derivative of V (t, S) with respect to (a)-(d) is defined by
In what follows, we assume that the solution of (a)-(d), S(t) = (z(t), w(t)), is a piecewise continuous function. That is, S(t) : R + → R >  whenever w(t) = , t = nT and z(nT
we have the following lemma.
Lemma  Suppose S(t) = (z(t), w(t)) is a solution of (a)-(d) with S(
+ ) ≥ . Then S(t) ≥  for all t ≥ .
Lemma  There exists a constant M >  such that, for sufficiently large t, z(t) ≤ M and w(t) ≤ M provided that
where (z(t), w(t)) is a solution of (a)-(d).
For t = nT , we choose a positive constant c for which
Thus, v(t) is uniformly ultimately bounded, and hence there exists a constant M >  such that z(t) ≤ M and w(t) ≤ M for sufficiently large t.

Stability when there is no active osteoclast
Now, let us consider the reduced impulsive system (a)-(d) when there is no active osteoclast (z = ):
Note that A >  and B > . We can see that
is a periodic solution of ()-() withw( + ) = 
This leads to the following result.
Lemma  System ()-() has a positive periodic solutionw(t), and for every solution w(t) of ()-(), we have w(t) →w(t) as t → ∞.
Therefore, system (a)-(d) has a periodic solution at the vanishing level of active osteoclasts ,w(t) = , μe
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Theorem  The solution (,w(t)) of (a)-(d) is locally asymptotically stable provided that
[ln(
.
Proof Consider a small perturbation from the point (,w(t))
Then we may write
where (t) satisfies
and () = I, the identity matrix. Hence, the fundamental solution matrix is
Since the term ( * ) is not required in further analysis, it is not necessary to find the exact expression for ( * ). Linearization of (c)-(d) yields
According to Floquet theory, the solution (,w(t)) of (a)-(d) is locally stable if |λ i | < , i = , , where λ i is an eigenvalue of
Note that the eigenvalues of M are
Since  < ρ < , B >  and ()-() hold, then
Hence,
Therefore, Floquet theory implies that the solution (,w(t)) of (a)-(d) is locally stable and the proof is complete.
Permanence of the system
Definition  The reduced impulsive system (a)-(d) is said to be permanent if there are constants m, M >  (independent of the initial values) and a finite time t  such that for all solutions with initial values z( + ) > , and
for all t > t  . Note that t  may depend on the initial values.
Theorem  Suppose that
Proof Suppose that S(t) = (z(t), w(t)) is a solution of system (a)-(d) with z( + ) >  and w( + ) > . Since () holds, Lemma  implies that there is a constant M >  such that, for
>  and (
and then we have
for some ε >  and for sufficiently large t. Hence,
for sufficiently large t. Therefore, we only need to show that there exists a constant m  >  such that z(t) > m  . In order to do so, for some m  > , we first let
Next, we do the two steps as follows.
Step . We will prove by contradiction that there exists t  such that z(t  ) ≥ m  . Suppose that z(t) < m  for all positive t. We observe from (b) and (d) that
Consider the comparison system
is a periodic solution of () 
for t ∈ (nT, (n + )T] and P(t) →P(t) = μe -B(t-nT)
as t → ∞.
The comparison theorem [] then implies that w(t) ≥ P(t).
Next, let us consider (a)
Since w(t) ≥ P(t), there is T  >  such that
Letting N ∈ Z + and NT ≥ T  , and integrating over (nT, (n + )T], n ≥ N , then we obtain
). Consider
For sufficiently small ε  > ,
Since () and () hold, we can choose a small m  >  such that ln η > , and hence
It contradicts the boundedness of z(t). Hence,
Step . If z(t) ≥ m  for all t > t  , then the proof is complete. Otherwise, z(t) < m  for some t > t  . Letting t * = inf t>t  {z(t) < m  }. There are two possible subcases.
Case : t * = n  T for some n  ∈ Z + . This means z(t) ≥ m  for t ∈ (t  , t * ] and, by the continuity of z(t), we have z(t * ) = m  .
Since there are M >  and m  >  such that z(t) < M, and m  < w(t) < M for sufficiently large t, we choose M >  and m  >  such that
considering () with P(t * + ) = w(t * + ), we have
for t ∈ (nT, (n + )T] and n  ≤ n ≤ n  + n  + n  .
For n  T ≤ t -t * ≤ T , we have
ThenP (t) -ε  < P(t) < w(t).
As in
Step , we have
From (a), we have
Integrating the above over [t
and hence
which contradicts the definition of m  . Hence, there is t  ∈ (t * , t
t), and by the continuity of z(t),
we have z(t) = m  . We choose l ∈ Z + such that l ≤ n  + n  and t * + lT ≥t, and suppose
Since η  <  and l ≤ n  + n  , lettinḡ
we have z(t) ≥m  for t ∈ (t * ,t). We can continue in the same way by usingt instead of t * .
Then we shall have z(t) ≥m  for all t large enough. Case : t * = nT for all n ∈ Z + . This means z(t) ≥ m  for t ∈ [t  , t * ) and z(t * ) = m  . Suppose t * ∈ (n  T, (n  + )T) for some n  ∈ Z + . There are two possible subcases.
Similarly to Case , for n  T ≤ t -t * , we obtain
Since n  T ≤ (n  +  + n  )T -t * , we have
which contradicts the definition of m  . Hence, there is
, and z(t) = m  . We choose
Since η  <  and t -t * ≤ l T, hence
we have z(t) ≥ m  for t ∈ (t * ,t). We can continue in the same way by usingt instead of t * .
Then we shall have z(t) ≥ m  for all t large enough. Case .: There is t ∈ (t
For t > t, we can continue in the same way since z(t) ≥ m  . Since m  <m  < m  , we have z(t) ≥ m  for t ≥ t  . The proof is complete.
Existence and stability of positive periodic solution
We now investigate the possibility of bifurcation of positive periodic solution to system (a)-(d) near (,w(t)). In order to do so, it is more convenient to exchange the state variables and consider the following system instead:
According to Lakmeche and Arino [],
Now, we can compute
We can also compute
Note that C * >  and B * <  if
Hence, the following result is obtained according to Lakmeche and Arino [] . 
Numerical simulations
In this section, numerical simulations are carried out in order to support our theoretical predictions. Firstly, all parameters are chosen to satisfy all conditions in Theorem . In Figure  , we can see that the solution of system (a)-(d) converges asymptotically to the oscillatory solution (,w(t)) as time passes conforming with our theoretical prediction. Figure  shows that the solution of system (a)-(d) is bounded within a positive range as time passes when all parameters are chosen to satisfy all conditions in Theorem . Here, the simulation result also agrees with our theoretical prediction. Finally, the solution trajectory of system (a)-(d) shown in Figure  exhibits the sustained oscillations as time passes when all parameters are chosen to satisfy all conditions in Theorem . A limit cycle occurs as theoretically predicted.
Conclusion
We have developed an impulsive system of bone remodeling process in order to investigate the effect of estrogen supplements. The model is then analyzed theoretically so that the conditions on the system parameters, for which the desirable behaviors of the solution of the system can be expected, are derived. We can see that the frequency of estrogen treatments  T , the dosages of estrogen supplements indicated by μ and ρ play important roles in controlling the number of active osteoclasts and active osteoblasts, the different frequencies and dosages of estrogen supplements might lead to the undesirable behavior of the system. For example, the solution of the system might be unbounded, which means that the number of active osteoclasts, bone resorbing cells, might increase to very high levels or the number of active osteoblasts, bone forming cells, decreases to very low levels resulting in the net bone resorption instead of bone formation, which is the expected outcome of the estrogen supplements.
Moreover, a condition needed to guarantee the existence of positive oscillation in the number of active osteoblasts and active osteoclasts resembling clinical observation stated in Theorem  is T > T max , where T max depends on μ and ρ. Hence, if the dosage of estrogen supplement reflected by μ and ρ is fixed, an appropriate frequency of estrogen supplement  T can be chosen so that T > T max as required by Theorem  to guarantee the desirable levels of active osteoblasts and active osteoclasts. Therefore, the dosage and the frequency of estrogen supplement are the keys to the effectiveness of estrogen supplement in osteoporosis patients.
